Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Sarclisa Escena is subcutaneous injection designed for 3 multiple myeloma treatment combinations

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

ByZachary Zubulake

July 10th 2026

PharmTech Weekly Roundup–July 10, 2026

BySusan Haigney

July 10th 2026

Teva Pharmaceutical Industries and Polpharma Biologics Collab on Ocrevus (ocrelizumab)

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

ByZachary Zubulake

July 9th 2026

Pharmaceutical research team collaborating on drug development project. Experts in safety gear combining chemical testing with digital analysis in science lab. | Image Credit: ©ultramansk -stock.adobe.com

It’s Time to Build a More Scalable, Connected CRO

ByTim Stroud

July 9th 2026

Creative image of embryonic stem cells, cellular therapy, 3d illustration | Image Credit: ©pinkeyes - stock.adobe.com

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies

ByCynthia A. Challener

July 8th 2026

Ion Exchange Resinates — The Technology Behind the Mystery

Articles in this issue

Related Content

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

It’s Time to Build a More Scalable, Connected CRO

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies

Trending on Pharmaceutical Technology

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

The FDA Moves to Modernize Drug Manufacturing Registration

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies